New York, USA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight
As potential therapies with novel mechanisms are being investigated to improve the management of IgAN, it is safe to predict that the IgA nephropathy market space will experience significant growth during the forecast period (2023–2032). However, the challenges of the rigid and burdensome structure of regulatory authorities will decide the fate of all these pipeline therapies and the impact they will have on overall revenue generation.
DelveInsight’s IgA Nephropathy Market Insights report includes a comprehensive understanding of current treatment practices, IgA nephropathy emerging drugs, market share of individual therapies, and current and forecasted IgA nephropathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China.
Key Takeaways from the IgA Nephropathy Market Report
- As per DelveInsight’s analysis, the IgA nephropathy market size was found to be USD 500 million in 2022 in the 7MM + China.
- As per DelveInsight estimates, the total prevalent cases of IgA nephropathy in the 7MM and China were ~1.8 million cases in 2022 and are projected to increase during the forecast period (2023–2032).
- Leading IgA nephropathy companies such as Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Visterra (a subsidiary of Otsuka Pharmaceutical), Alnylam Pharmaceuticals, Vera Therapeutics, RemeGen, Chinook Therapeutics, and others are developing novel IgA nephropathy drugs that can be available in the IgA nephropathy market in the coming years.
- Some of the key therapies for IgA nephropathy treatment include Narsoplimab, Iptacopan (LNP023), Atrasentan, Sibeprenlimab (VIS-649), Cemdisiran, Atacicept (VT-001), Telitacicept (RC18), BION-1301, and others.
- In June 2021, the EMA designated sibeprenlimab as an orphan medicine for the treatment of primary IgA nephropathy in the European Union.
Discover which therapies are expected to grab the major IgA nephropathy market share @ IgA Nephropathy Market Report
IgA Nephropathy Overview
IgA Nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the immune system's misguided response, causing damage to the small blood vessels and filtration system within the kidneys. It results from the presence of an abnormal protein that disrupts kidney filtration. Globally, IgA Nephropathy is the most commonly diagnosed glomerular disease, although its prevalence varies widely across different geographical regions. Diagnosing IgA nephropathy typically involves identifying IgA as the predominant or co-dominant immunoglobulin within the glomerular mesangium through a kidney biopsy. While renal biopsy remains the established method for diagnosing IgAN, there is an ongoing search for novel biomarkers that could enable noninvasive prediction of IgAN, given the elusive nature of its pathogenesis.
IgA Nephropathy Epidemiology Segmentation
The IgA nephropathy epidemiology section provides insights into the historical and current IgA nephropathy patient pool and forecasted trends for the 7MM + China. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The IgA nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM + China segmented into:
- Total IgAN Prevalent Cases
- Total IgAN Diagnosed Prevalent Cases
- IgAN Gender-specific Cases
- IgAN Age-specific cases
Download the report to understand which factors are driving IgA nephropathy epidemiology trends @ IgA Nephropathy Epidemiological Insights
IgA Nephropathy Treatment Market
According to real-world data analysis, two commonly used therapies for IgA nephropathy (IgAN) to manage symptoms such as hypertension are angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). To slow down the progression of the disease, corticosteroids and other immunosuppressive agents like mycophenolate mofetil (MMF) and cyclophosphamide are also utilized. TARPEYO (budesonide) delayed-release tablet was the first medication approved by the FDA for the treatment of IgAN. This approval, granted in December 2021 via an accelerated process, was in response to the urgent need for safe and effective treatments. It is specifically indicated for IgAN patients at risk of rapid disease progression, typically those with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
Despite being the first IgA nephropathy treatment to receive regulatory approval, TARPEYO still encounters certain drawbacks, particularly in terms of its cost. Budesonide, a readily accessible corticosteroid available in the form of TARPEYO, comes at a significantly higher price point, leading to apprehension among patients and healthcare professionals alike. Consequently, the elevated cost of TARPEYO remains a substantial hurdle for more widespread utilization by IgAN patients. Additionally, the recently approved FILSPARI (sparsentan) by Travere Therapeutics, Inc./Vifor Pharma now offers another treatment option for the IgAN population.
Learn more about the FDA-approved drugs for IgAN @ Drugs for IgA Nephropathy Treatment
Key IgA Nephropathy Therapies and Companies
- Narsoplimab: Omeros Corporation
- Iptacopan (LNP023): Novartis Pharmaceuticals
- Atrasentan: Chinook Therapeutics
- Sibeprenlimab (VIS-649): Visterra (a subsidiary of Otsuka Pharmaceutical)
- Cemdisiran: Alnylam Pharmaceuticals
- Atacicept (VT-001): Vera Therapeutics
- Telitacicept (RC18): RemeGen
- BION-1301: Chinook Therapeutics
To know more about IgA nephropathy clinical trials, visit @ IgA Nephropathy Treatment Drugs
IgA Nephropathy Market Dynamics
The dynamics of the IgA nephropathy market are expected to change in the coming years. The robust pipeline features several cutting-edge treatments, such as iptacopan and narsoplimab, within the rapidly evolving landscape of emerging therapies. These advancements in science have enabled us to pinpoint novel biomarkers for disease diagnosis and progression monitoring, ultimately leading to the development of disease-specific treatments. Given its orphan status, these innovative therapies have the potential to secure Orphan designation, granting them exclusive marketing rights for a period of up to 7 years. Furthermore, with the recent Phase III Part B results of TARPEYO, we anticipate securing full approval in the US, EU, and the UK. This will not only expand its indications but also facilitate entry into the Chinese IgAN market, broadening access for a larger patient population.
However, several factors are impeding the growth of the IgA nephropathy market. TARPEYO's pricing considerably exceeds that of other budesonide formulations, posing a significant barrier to its market expansion. Safety concerns often result in limited patient access, as seen with FILSPARI, which the FDA placed under the REMS program due to its hepatotoxic and embryo-fetal toxic effects. Patients with respiratory or intestinal infections frequently experience worsened disease outcomes, and the immune system’s response plays a crucial role. Approved drugs, due to their accelerated approval status, have a narrow scope of use, benefiting only a limited patient group.
Furthermore, the IgA nephropathy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the IgA nephropathy market growth.
| IgA Nephropathy Report Metrics | Details |
| Study Period | 2019–2032 |
| IgA Nephropathy Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] and China |
| IgA Nephropathy Market Size in 2022 | USD 500 Million |
| Key IgA Nephropathy Companies | Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Visterra (a subsidiary of Otsuka Pharmaceutical), Alnylam Pharmaceuticals, Vera Therapeutics, RemeGen, Chinook Therapeutics, and others |
| Key IgA Nephropathy Therapies | Narsoplimab, Iptacopan (LNP023), Atrasentan, Sibeprenlimab (VIS-649), Cemdisiran, Atacicept (VT-001), Telitacicept (RC18), BION-1301, and others |
Scope of the IgA Nephropathy Market Report
- Therapeutic Assessment: IgA Nephropathy current marketed and emerging therapies
- IgA Nephropathy Market Dynamics: Attribute Analysis of Emerging IgA Nephropathy Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement
Discover more about IgA nephropathy drugs in development @ IgAN Clinical Trials
Table of Contents
| 1. | IgA Nephropathy Market Key Insights |
| 2. | IgA Nephropathy Market Report Introduction |
| 3. | IgA Nephropathy Market Overview at a Glance |
| 4. | IgA Nephropathy Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | IgA Nephropathy Treatment and Management |
| 7. | IgA Nephropathy Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | IgA Nephropathy Marketed Drugs |
| 10. | IgA Nephropathy Emerging Drugs |
| 11. | Seven Major IgA Nephropathy Market Analysis |
| 12. | IgA Nephropathy Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
IgA Nephropathy Epidemiology Forecast
IgA Nephropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted IgA nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
IgA Nephropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies, including Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, among others.
Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute kidney injury companies, including Cerenis Therapeutics, Alloksys, Vifor Pharma, Exponential Biotherapies, Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, Nephraegis Therapeutics, Vasomune, Unicycive, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, ABIONYX, among others.
Acute Kidney Injury Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key acute kidney injury companies, including Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX, among others.
Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, among others.
Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key chronic kidney disease companies, including KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
